학술논문
ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease.
Document Type
Article
Author
Source
Subject
*APOLIPOPROTEIN E
*ALZHEIMER'S disease
*CLINICAL trials
*ROFECOXIB
*SOMATOTROPIN
*
*
*
*
Language
ISSN
1470-269X
Abstract
The article offers information on a study which investigated the effect of the ApoE allele on cognition in Alzheimer's disease (AD). It references the two previous randomized clinical trials conducted by Merck, the Protocol 091/rofecoxib and the Protocol 030/MK-677 growth hormone secretagogue. Findings showed the association of ApoE allele with faster decline in AD, and with lower baseline scores.